Online inquiry

IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10739MR)

This product GTTS-WQ10739MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ADAMTSL5&ALB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Lama glama; Humanized
RefSeq NM_213604.3; NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 339366; 213
UniProt ID Q6ZMM2; P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10739MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13517MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ5617MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ14008MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ8194MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ8898MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ9124MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ3329MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ7453MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW